You are not allowed to view Ad
News View all news
FDA approves new dosage strength of sublingual film as maintenance treatment for opioid dependence
FDA approved on Friday buprenorphine and naloxone (Cassipa—Teva Pharmaceuticals USA) sublingual film for the maintenance treatment of opioid dependence. The approval provides a new dosage strength, 16 mg/4 mg, of buprenorphine and naloxone sublingual film.
FDA statement on its ongoing investigation into valsartan impurities and recalls
In a statement, FDA Commissioner Scott Gottlieb, MD, and Janet Woodcock, MD, director of FDA's Center for Drug Evaluation and Research (CDER), provide an update on the agency's investigation into an impurity, NDMA, found in some generic versions of the blood pressure medication valsartan.
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease
Aspirin has been shown to lower the risk of a second heart attack or stroke. But a randomized trial with more than 12,500 people — considered to be at moderate risk for cardiovascular disease — found the rate of heart problems did not differ between people taking aspirin and those on placebo.
U.S. health secretary says agency has power to eliminate drug rebates
HHS Secretary Alex Azar says it is within his agency's power to eliminate rebates on prescription drug purchases, asserting they create a perverse incentive to continuously raise drug prices. HHS last month proposed regulations that would scale back protections for rebates that might otherwise be illegal under a federal anti-kickback law.
April 3, 2018
Keep making noise about how pharmacists are fighting the opioid…
We asked, and you delivered. THANK YOU! APhA has been on social media and pharmacist.com rallying the troops to contact their representatives in Congress and tell them that to make a meaningful…0 comments
May 15, 2018
Test - XXX
The Speaker-elect serves a one-year term in that capacity before taking over as Speaker of the House and Trustee for two years. The entire term for this position is three years, beginning the day after the close of the 2018 APhA Annual Meeting and concluding on the last day of the 2021 APhA Annual Meeting.
The Speaker-elect serves a one-year term in that capacity before taking over as Speaker of the House and Trustee for two years
APhA is the leading advocate for the pharmacy profession and a driving force in creating opportunities for pharmacists to play a key role in integrated patient care, and ensuring the profession is recognized as essential in optimal medication use. We strive to make your job as a pharmacist easier, by providing the latest industry news, continuing education and professional development opportunities, practice tools, and more, so that you can focus on caring for your patients.